TCRX Stock Overview
A clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TScan Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.51 |
| 52 Week High | US$9.69 |
| 52 Week Low | US$1.93 |
| Beta | 0.91 |
| 1 Month Change | 33.57% |
| 3 Month Change | 39.44% |
| 1 Year Change | 281.93% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -9.43% |
Recent News & Updates
Recent updates
Subdued Growth No Barrier To TScan Therapeutics, Inc.'s (NASDAQ:TCRX) Price
Mar 23
Is TScan Therapeutics (NASDAQ:TCRX) Using Too Much Debt?
Feb 17TScan Therapeutics, Inc. (NASDAQ:TCRX) Just Reported, And Analysts Assigned A US$10.75 Price Target
Mar 11TScan Therapeutics GAAP EPS of -$0.63 beats by $0.13, revenue of $4.05M beats by $1.05M
Aug 10TScan Therapeutics appoints Debora Barton as Chief Medical Officer
Jul 07Here's Why We're Watching TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Situation
May 22Will TScan Therapeutics (NASDAQ:TCRX) Spend Its Cash Wisely?
Jan 17We're Keeping An Eye On TScan Therapeutics' (NASDAQ:TCRX) Cash Burn Rate
Oct 18Shareholder Returns
| TCRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 6.5% | 0.7% | 1.2% |
| 1Y | 281.9% | 5.0% | 27.7% |
Return vs Industry: TCRX exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: TCRX exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| TCRX volatility | |
|---|---|
| TCRX Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TCRX's share price has been volatile over the past 3 months.
Volatility Over Time: TCRX's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 154 | Gavin MacBeath | www.tscan.com |
TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company’s lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors.
TScan Therapeutics, Inc. Fundamentals Summary
| TCRX fundamental statistics | |
|---|---|
| Market cap | US$530.25m |
| Earnings (TTM) | -US$96.80m |
| Revenue (TTM) | US$14.81m |
36.7x
P/S Ratio-5.6x
P/E RatioIs TCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TCRX income statement (TTM) | |
|---|---|
| Revenue | US$14.81m |
| Cost of Revenue | US$91.23m |
| Gross Profit | -US$76.42m |
| Other Expenses | US$20.38m |
| Earnings | -US$96.80m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.69 |
| Gross Margin | -515.93% |
| Net Profit Margin | -653.50% |
| Debt/Equity Ratio | 24.6% |
How did TCRX perform over the long term?
See historical performance and comparison